• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Acumen Pharmaceuticals, Inc. - Common Stock (NQ:ABOS)

0.1865 -0.0068 (-3.52%)
Delayed Quote Updated: 4:00 PM EST, Nov 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,712,986
Open 0.1861
Bid (Size) 0.1750 (700)
Ask (Size) 0.1828 (100)
Prev. Close 0.1933
Today's Range 0.1600 - 0.1927
52wk Range 0.1600 - 3.600
Shares Outstanding 40,501,258
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Unusual-Volume Stocks: Latest Session's Sharp Declines and Double-Digit Gains ↗
November 05, 2026
Via Chartmill
News headline image
Acumen Pharmaceuticals: 3 Key Takeaways for Long-Term Investors ↗
November 04, 2026
A single confirmatory Phase III trial design could streamline the path to regulatory approval if November data validates the oligomer-targeting approach. 
Via The Motley Fool
Topics Earnings

Performance

52-Week Range 94.8% below 52-week high
0.1865
0.1652W Low 3.6052W High
1 Week 19.9% below 1-week high
0.161W Low 0.231W High

Acumen Pharmaceuticals, Inc. - Common Stock (ABOS) traded between $0.16 and $3.60 over the past 52 weeks and last traded at $0.19, 94.8% below its 52-week high. Over the past week it ranged between $0.16 and $0.23.

Past 12 Months
-12.9%
-90.7%
-94.2%
-92.5%
-90.8%
-88.0%
1W -$0.03
1M -$1.83
3M -$3.00
6M -$2.30
YTD -$1.83
1Y -$1.36

ABOS was -88.0% over the past year, -92.5% over six months, -90.8% year to date, -12.9% in the last week.

12 Months vs Market
ABOS
-88.0%
DIA
+4.2%
SPY
+4.1%
QQQ
+1.4%
IWM
+9.9%

Over the past 12 months ABOS returned -88.0% versus DIA (Dow) +4.2%, SPY (S&P 500) +4.1%, QQQ (Nasdaq 100) +1.4% and IWM (Russell 2000) +9.9%.

Volume & Liquidity 1.02× 3-mo avg
Today 2,712,986 3-mo avg 2.7M
1W
2.6M
1M
6.4M
3M
2.7M
6M
1.6M
YTD
1.2M
1Y
1.1M

ABOS most recently traded 2,712,986 shares against a 3-month average daily volume of 2.7M.

More News

Read More
US Unusual Volume Stocks: ONEG, CENN, SLGB and INLF in Latest Scan ↗
November 02, 2026
Via Chartmill
Small-Cap Market Movers: Top Gainers and Losers on Nov. 2, 2026 ↗
November 02, 2026
Via Chartmill
Acumen Pharmaceuticals (NASDAQ:ABOS) Narrows Q3 Loss as ALTITUDE-AD Readout Looms ↗
October 26, 2026
Via Chartmill
Acumen Pharmaceuticals (NASDAQ:ABOS) Q1 2026 Loss Narrows as Phase 2 Alzheimer's Trial Readout Looms ↗
May 12, 2026
Via Chartmill
Postmarket Movers: After-Hours Gainers and Losers ↗
October 30, 2026
Via Chartmill
Most Active Stocks on Oct. 30, 2026: Intel, ChowChow Cloud and Acumen in Focus ↗
October 30, 2026
Via Chartmill
News headline image
Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint
October 30, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals (ABOS) Q3 2026 Earnings Call Transcript ↗
October 26, 2026
Via The Motley Fool
Topics Earnings
News headline image
Acumen Pharmaceuticals Q3 Earnings Call Highlights ↗
October 26, 2026
Via MarketBeat
Topics Earnings
News headline image
Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
October 26, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
October 22, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026
October 19, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
September 10, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
September 02, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Q2 Earnings Call Highlights ↗
August 12, 2026
Via MarketBeat
Topics Earnings
News headline image
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
August 12, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
August 05, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
July 15, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
July 07, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease
June 16, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen (ABOS) Q1 2026 Earnings Transcript ↗
May 12, 2026
Via The Motley Fool
News headline image
Acumen Pharmaceuticals Q1 Earnings Call Highlights ↗
May 12, 2026
Via MarketBeat
Topics Earnings
News headline image
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
May 12, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Acumen Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Acumen Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Acumen Pharmaceuticals, Inc. - Common Stock trade on?
Acumen Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Acumen Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Acumen Pharmaceuticals, Inc. - Common Stock is ABOS on the Nasdaq Stock Market
What is the current price of Acumen Pharmaceuticals, Inc. - Common Stock?
The current price of Acumen Pharmaceuticals, Inc. - Common Stock is 0.1865
When was Acumen Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Acumen Pharmaceuticals, Inc. - Common Stock was at 11/20/26 04:00 PM ET
What is the market capitalization of Acumen Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Acumen Pharmaceuticals, Inc. - Common Stock is 7.55M
How many shares of Acumen Pharmaceuticals, Inc. - Common Stock are outstanding?
Acumen Pharmaceuticals, Inc. - Common Stock has 8M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap